Seres Therapeutics (MCRB) Debt to Equity: 2015-2024
Historic Debt to Equity for Seres Therapeutics (MCRB) over the last 4 years, with Jun 2024 value amounting to -$1.18.
- Seres Therapeutics' Debt to Equity fell 126.42% to -$1.18 in Q2 2024 from the same period last year, while for Jun 2024 it was -$1.18, marking a year-over-year decrease of 126.42%. This contributed to the annual value of -$2.26 for FY2023, which is 148.25% down from last year.
- Per Seres Therapeutics' latest filing, its Debt to Equity stood at -$1.18 for Q2 2024, which was up 31.07% from -$1.71 recorded in Q1 2024.
- Over the past 5 years, Seres Therapeutics' Debt to Equity peaked at $4.69 during Q4 2022, and registered a low of -$6.69 during Q3 2023.
- Moreover, its 3-year median value for Debt to Equity was -$0.22 (2022), whereas its average is -$0.02.
- Its Debt to Equity has fluctuated over the past 5 years, first spiked by 2,403.74% in 2022, then tumbled by 988.72% in 2023.
- Seres Therapeutics' Debt to Equity (Quarterly) stood at $0.14 in 2020, then skyrocketed by 32.90% to $0.19 in 2021, then skyrocketed by 2,403.74% to $4.69 in 2022, then crashed by 148.25% to -$2.26 in 2023, then crashed by 126.42% to -$1.18 in 2024.
- Its Debt to Equity was -$1.18 in Q2 2024, compared to -$1.71 in Q1 2024 and -$2.26 in Q4 2023.